New sonic device aims to make lung mucus clearance easier
NCT ID NCT07568119
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new device called SonoHeal that uses sound waves to help people with cystic fibrosis, bronchiectasis, or COPD clear mucus from their lungs. Fifteen participants will try the device at home to see if it is easy to use and acceptable. The study also compares it to standard chest wall oscillation therapy.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- SonoHeal device (acoustic oscillation therapy)
- What this could lead to
- If successful, this could provide a new, easier-to-use option for clearing mucus from the lungs in people with cystic fibrosis, bronchiectasis, or COPD.
- What could go wrong
- This is a very small, early feasibility study with only 15 participants. It focuses on usability, not on proving the device works better than existing treatments. The device may not improve lung function or symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 15 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Feb 2024
- Expected to finish
-
Jun 2026
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population will be drawn from patients receiving routine clinical care for chronic airway diseases at Ventura County Medical Center and UCLA. This population includes adolescents and adults with established diagnoses of Cystic Fibrosis, Non-cystic fibrosis bronchiectasis, and Chronic Obstructive Pulmonary Disease who require ongoing airway clearance therapy (ACT) as part of standard disease management. Patients in this population are typically managed in outpatient pulmonary or specialty clinics and have longitudinal follow-up within the health system. They commonly experience chronic sputum production and utilize daily ACT in combination with inhaled therapies such as bronchodilators and mucolytics. The population represents individuals with stable, chronic disease who are capable of performing routine airway clearance treatments in both clinical and home settings.
- Ages
-
11 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Diagnosis of CF established by either genetic screening or positive chloride sweat test (Sweat chloride concentrations \> 60mmol/L). * Diagnosis of NCFB or COPD requiring regular use of airway clearance therapy. * Age older than 11 years. * History of chronic daily sputum production. * Currently on a home therapeutic regimen that includes some form of ACT performed at least once daily that also includes concomitant use of an inhaled mucolytic and inhaled bronchodilator. * Stage I eligibility for the 3 subjects will require patients who have had ≥2 ACT session with the VEST® in-clinic with lung function measured pre-post therapy. * FVC and FEV1 \> 35%-predicted, and with stable lung function (no greater than a 10% variation in lung function parameters over the preceding 2 months). * Evaluated at the Ventura County Medical Center 2 or more times in the preceding 12 months. * Signed informed consent given by the subject, or the parents, or a legally acceptable representative. If required by the Institutional Review Board/Ethics Committee (IRB/IEC), assent will be given by the subject. * Ability to understand study requirements and comply with study procedures. Individuals of all ethnicities are included. Exclusion Criteria: * Hospitalization for CF pulmonary complications in the 2 months preceding enrollment. * Hemoptysis \> 60 cc in a single episode in the 4 weeks preceding enrollment. * Chronic chest pain. * Participation in another clinical trial in the previous 30 days. * Use of intravenous antibiotics in the 2 months preceding enrollment. * Inability or unwillingness of the participant to give written informed consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease (COPD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ventura County Medical Center
Santa Ana, California, 92701-3515, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- COPD may affect the brain and muscles, not just the lungs
- Glucose sensor may flag diabetes risk in cystic fibrosis
- New drug RO7830698 put to the test for COPD
- Can rain sounds make breathing exercises work better for COPD?
- Is RSV a hidden driver of severe COPD attacks?
- Switching to a nebulizer may help COPD patients who get no relief from inhalers